This Joint Venture strengthens Healthcare Triangle's and QuantumNexis' position to access the fastest growing Saudi Arabia 70-billion-dollar Healthcare Market by 2030 PLEASANTON, Calif., Feb. 5, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries, today announced that its subsidiary QuantumNexis is participating a J ...

"This collaboration reflects our shared vision of transforming healthcare delivery globally," said Suresh Venkatachari, Chairman of QuantumNexis. "By combining Healthcare Triangle and its subsidiary QuantumNexis' innovation and execution capabilities with the robust Better platform, we are uniquely positioned to bring cutting-edge digital health solutions to emerging markets and make a meaningful impact on patient care." Partnership positions Healthcare Triangle as preferred service provider across high-gro ...

Healthcare Triangle, Inc. Announces Participation and Presentation at the Deal Flow Discovery Conference in Atlantic City [Accessibility Statement] Skip NavigationPLEASANTON, Calif., Jan. 28, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announces its participation in the Deal Flow Discovery Conference, taking place January 28th and 29th in Atlantic City, New Jersey, and presenting ...

PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announces that it has entered into an Definitive Agreement with Teyame AI LLC, a St Kitts and Nevis corporation ("Teyame"), as part of its planned acquisition of the shares of Teyame 360 SL and Datono Mediacion SL, companies incorporated in Spain ("Assets"), which are run together as a Spain-based leader in ...

Core Insights - Healthcare and biotechnology stocks experienced significant movements in after-hours trading, with several companies showing strong gains despite limited news flow [1] Company Summaries - Novo Nordisk A/S (NVO) saw a notable increase of 9.48%, closing at $52.66, following FDA approval of its Wegovy pill, the first oral GLP-1 medicine for obesity in the U.S., which is also approved to reduce cardiovascular risks [2] - Neumora Therapeutics, Inc. (NMRA) advanced 16.02% to $2.10, indicating investor interest possibly driven by broader sector momentum or speculative trading, as there were no specific news updates [3] - BioRestorative Therapies, Inc. (BRTX) rose 6.90% to $1.24, with investors reacting to a prior announcement regarding an FDA Type B meeting to discuss a potential accelerated BLA pathway for its BRTX-100 program for chronic lumbar disc disease [4] - RenovoRx, Inc. (RNXT) added 4.44% to close at $0.94, with earlier news of an accepted abstract submission for the ASCO Gastrointestinal Cancers Symposium 2026 contributing to investor interest [5] - IDEAYA Biosciences, Inc. (IDYA) gained 6.49% to $37.81, following the full enrollment of 435 patients in its Phase 2/3 trial for darovasertib, with expected data reporting in Q1 2026 [6] - Healthcare Triangle, Inc. (HCTI) climbed 6.72% to $1.43, with a recent announcement of an Advance Agreement for acquiring AI-powered customer experience firms, enhancing its position in global AI-driven solutions [7] - Alphatec Holdings, Inc. (ATEC) posted a modest gain of 2.80%, rising to $21.28, benefiting from ongoing investor confidence in the spine surgery provider [8]

Core Viewpoint - Healthcare Triangle, Inc. is acquiring Teyame AI LLC and its subsidiaries, enhancing its position in AI-powered customer and patient engagement solutions [1][2][3] Financial Overview - The total consideration for the acquisition is expected to be approximately $50 million, comprising cash, common stock, non-voting convertible preferred stock, and contingent earnout-based equity [2] - The acquisition is projected to generate about $34 million in incremental annual revenue and $4.2 million in incremental EBITDA for fiscal year 2025 [3] Strategic Importance - This acquisition marks a significant transition for Healthcare Triangle from a healthcare IT provider to a comprehensive digital health innovator, aiming to enhance financial performance and shareholder value [3] - The integration of AI-powered engagement platforms with existing healthcare technologies is expected to create an intelligent ecosystem for patients and providers [5] Technological Advancements - The acquired assets include advanced AI capabilities such as chatbot automation, multilingual patient engagement tools, and real-time analytics, which will enhance HCTI's clinical systems [8][10] - The transaction aims to leverage Agentic Generative AI to improve operational efficiency and drive innovation in healthcare services [4][10] Market Positioning - The acquisition positions Healthcare Triangle as a global leader in AI-powered customer experience solutions, targeting high-growth international markets [7]

Core Viewpoint - Healthcare Triangle, Inc. has entered into a Sales Agreement with Spartan Capital Securities for an at-the-market offering program, allowing the company to raise up to $20 million through the sale of its common stock [1][2]. Group 1: Sales Agreement Details - The Sales Agreement was executed on November 18, 2025, enabling Healthcare Triangle to offer and sell shares with an aggregate market value of up to $20 million [2]. - Shares may be sold on the Nasdaq Capital Market or other trading venues at prevailing market prices, providing flexible access to capital for the company's operational and financial strategy [2]. Group 2: Company Focus and Support - Healthcare Triangle is focused on strengthening its platform and expanding capabilities in cloud-based healthcare solutions [3]. - Spartan Capital Securities expresses support for Healthcare Triangle through the ATM program, indicating a commitment to the company's capital markets initiatives [3]. Group 3: Regulatory Compliance - The shares offered under the ATM program will be issued pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission [4].

Financial Performance - Net revenue for the three months ended September 30, 2025, was $3,489,000, representing a 44.7% increase from $2,413,000 in the same period of 2024[20] - Net revenue for the nine months ended September 30, 2025, reached $10,752,000, up 13.1% from $9,506,000 in the prior year[20] - The company reported a net loss of $1,906,000 for the three months ended September 30, 2025, compared to a net loss of $1,249,000 in the same period of 2024[20] - The company reported a net loss of $(4,973) for the nine months ended September 30, 2025[23] - The total net loss for the nine months ended September 30, 2025, was $4,973,000, compared to a net loss of $4,621,000 for the same period in 2024, indicating a slight increase in losses[123] Assets and Liabilities - Total current assets increased significantly to $7,942,000 as of September 30, 2025, compared to $1,949,000 as of December 31, 2024[18] - Total liabilities decreased to $5,112,000 as of September 30, 2025, down from $7,075,000 as of December 31, 2024[18] - Cash and cash equivalents surged to $1,629,000 as of September 30, 2025, compared to $20,000 as of December 31, 2024[18] - The company’s accumulated deficit increased to $38,520,000 as of September 30, 2025, from $33,571,000 as of December 31, 2024[18] - As of September 30, 2025, the total equity amounted to $8,726, with a net loss of $38,520 for the three months ended[23] Revenue Breakdown - Software services revenue for the nine months ended September 30, 2025, was $6,242,000, reflecting a 107% increase from $3,010,000 in the same period of 2024[120] - Managed services and support revenue decreased by 33% to $4,235,000 for the nine months ended September 30, 2025, down from $6,295,000 in the same period of 2024[120] - Revenue from the top five customers accounted for approximately 56% of total revenue, down from 61% in the same quarter of 2024[67] - Revenue from Software Services increased by $1.20 million, or 155%, to $1.97 million for the quarter ended September 30, 2025, while revenue from Managed Services and Support decreased by $0.19 million, or 12%, to $1.37 million[198] Expenses - Operating expenses for the three months ended September 30, 2025, totaled $3,209,000, an increase from $1,889,000 in the prior year[20] - General and administrative expenses rose to $2,085,000 for the three months ended September 30, 2025, compared to $1,077,000 in the same period of 2024[20] - Advertising and marketing expenses for the three months ended September 30, 2025, were $649,000, compared to $78,000 for the same period in 2024[143] - Research and Development expenses decreased by $0.11 million, or 66%, to $0.05 million for the quarter ended September 30, 2025[190] - Sales and Marketing expenses increased by $0.72 million, or 248%, to $1.02 million for the quarter ended September 30, 2025[191] Cash Flow - Net cash used in operating activities was $9,689,000 for the nine months ended September 30, 2025, a significant increase from $270,000 in the same period of 2024[26] - The company reported a net cash provided by financing activities of $12,587,000, a substantial increase from a net cash used of $936,000 in the prior year[26] - The net increase in cash and cash equivalents for the nine months ended September 30, 2025, was $1.61 million, compared to a decrease of $(1.21) million in 2024[211] Acquisitions and Investments - The company entered into an Asset Transfer Agreement to acquire Niyama Healthcare, Inc. and its 100% equity interest in Ezovion Solutions Private Limited, enhancing its market presence in mental health and hospital information systems[28] - The total consideration for the acquisition of Niyama Healthcare, Inc. is $5,700,000, which includes $1,500,000 in cash and 1,388,041 shares of restricted common stock valued at $3,000,000[72] - The company acquired intangible assets for $1,283,000 during the nine months ended September 30, 2025[26] Stock and Equity - The company issued 3,000 shares to be issued as part of its equity structure[24] - The company issued a convertible note on December 28, 2023, with a principal amount of $2,000,000, resulting in gross proceeds of $1,700,000[111] - As of September 30, 2025, the total issued and outstanding Series A Preferred Stock was 20,000 shares, with super voting rights equivalent to 1,000 votes per share[99] Future Outlook - The Company expects future profit margins to increase materially as new contracts are negotiated at higher margins[174] - Research and development expenses are expected to increase in absolute dollars as the Company focuses on developing new product offerings[176] - Sales and marketing expenses are anticipated to continue increasing as the Company strategically invests to expand its business[178] - The Company aims to enhance its customer base by encouraging existing customers to deploy additional solutions and attracting new customers[164]

Core Viewpoint - The market tends to favor companies with compelling narratives, often prioritizing perceived size over actual performance [1] Group 1 - Companies that present strong stories can attract market attention and investment, regardless of their actual size [1] - The distinction between companies that sound large and those that are genuinely large can lead to mispricing in the market [1]

Core Insights - Healthcare Triangle Inc. has announced a significant growth strategy, indicating a proactive approach to expanding its market presence [1] Company Summary - The company is positioned in the healthcare sector and is focusing on aggressive growth initiatives, which may suggest a shift in its operational strategy [1]